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Abstract
Objectives: To investigate the presence and the nature of cognitive impairment in a large sample of patients with Multiple
Sclerosis (MS), and to identify clinical and demographic determinants of cognitive impairment in MS.
Methods: 303 patients with MS and 279 healthy controls were administered the Brief Repeatable Battery of
Neuropsychological tests (BRB-N); measures of pre-morbid verbal competence and neuropsychiatric measures were also
administered.
Results: Patients and healthy controls were matched for age, gender, education and pre-morbid verbal Intelligence
Quotient. Patients presenting with cognitive impairment were 108/303 (35.6%). In the overall group of participants, the
significant predictors of the most sensitive BRB-N scores were: presence of MS, age, education, and Vocabulary. The
significant predictors when considering MS patients only were: course of MS, age, education, vocabulary, and depression.
Using logistic regression analyses, significant determinants of the presence of cognitive impairment in relapsing-remitting
MS patients were: duration of illness (OR= 1.053, 95% CI = 1.010–1.097, p = 0.015), Expanded Disability Status Scale score
(OR= 1.247, 95% CI = 1.024–1.517, p = 0.028), and vocabulary (OR= 0.960, 95% CI = 0.936–0.984, p = 0.001), while in the
smaller group of progressive MS patients these predictors did not play a significant role in determining the cognitive
outcome.
Conclusions: Our results corroborate the evidence about the presence and the nature of cognitive impairment in a large
sample of patients with MS. Furthermore, our findings identify significant clinical and demographic determinants of
cognitive impairment in a large sample of MS patients for the first time. Implications for further research and clinical practice
were discussed.
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Introduction
Multiple Sclerosis (MS) is a chronic neurodegenerative disease
typically characterized by white matter lesions, axonal damage
and cerebral atrophy [1,2]. MS affects both the neurological and
the psychological domains. Most patients are diagnosed between
20 and 50 years of age, and women are affected two to three times
as often as men [3]. In a study conducted in central Italy, the
overall prevalence rate was 95 cases per 100,000. In keeping with
previous results, a higher prevalence rate for females than males
was recorded. Age-specific prevalence rate was higher in the 25–
34 year, 35–44 year and 45–54 year age groups [4].
Cognitive impairment is a common clinical feature of MS, with
current prevalence rates ranging from 30% to 70% [5,6]. MS
negatively affects various aspects of cognitive functioning including
attention [7], information processing abilities [8,9], processing
speed [10], new learning [11] and memory [12]. It is relevant to
note that cognitive impairment does not simply reflect problems in
performing cognitive tasks, but is often associated with reduced
functional status [13,14]. In addition, cognitive impairment often
has a deleterious impact on patients’ occupational and social
functioning, as well as on their overall quality of life [13,15]. For
example, it has been shown that people with MS who have
cognitive impairment - as opposed to those with only the physical
signs of the disease - were less likely to be employed, were engaged
in fewer social and vocational activities, had greater difficulties in
carrying out routine household tasks, and were more vulnerable to
psychiatric illness [6]. Neuropsychological batteries have been
developed to investigate cognitive impairment in MS. One of the
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most widely used cognitive batteries is the Brief Repeatable
Battery of Neuropsychological tests (BRB-N; [16]), used for both
research and clinical purposes. It encompasses tests tapping the
cognitive functions affected by MS, and recent research have
shown that some of these tests (e.g., the Selective Reminding Test,
the Symbol Digit Modalities Test, and the Paced Auditory Serial
Addition Test) have a higher sensitivity than others to detect
deficits in this clinical population [17]. Thus, the need of cognitive
assessment in patients with MS is gaining increasing attention in
standard clinical routine.
To date there is no clear and robust evidence about what
demographic and clinical variables may lead to an increased
probability to developing cognitive impairment during the course
of MS. To the best of our knowledge, previous studies have not
specifically investigated the significant determinants of cognitive
impairment in large samples of patients with MS. In the present
study we recruited a large sample of patients with MS (N=303)
and a large sample of healthy controls (N= 279). All of the
participants underwent the BRB-N with the twofold aim of
investigating the presence and the nature of cognitive impairment
in a large sample of MS patients, and identifying significant
determinants of cognitive impairment in this clinical population.
Methods
Ethics Statement
Informed written consent was obtained from all of the
participants. The study was granted approval by the Research
Ethics Committee of the ‘‘San Luigi Gonzaga’’ Hospital Medical
School of Orbassano (Italy), and was conducted in accordance
with the Declaration of Helsinki.
Participants
Three hundred and three patients with MS (91 males and 212
females) were consecutively recruited from May 2010 to June 2012
from the CReSM (Regional Reference Center for Multiple
Sclerosis, affiliated with the University Hospital ‘‘San Luigi
Gonzaga’’ of Orbassano, Italy), an Italian reference center for
the diagnosis and treatment of patients with MS. All of the patients
underwent detailed biological and clinical investigations, and
received a definite diagnosis of MS, according to the standard
International criteria [18], by neurologists expert in the diagnosis
of MS (more than 10 years of clinical experience). Patients with
possible MS or clinically isolated syndrome were not included in
the study. In terms of MS status, 267 patients out of 303 (i.e. 88%)
were classified as relapsing-remitting (RR), 9 (3%) as primary
progressive (PP), 21 (7%) as secondary progressive (SP), and 6 (2%)
as relapsing-progressive (RP). In total, 88% of the patients were
classified as having a relapsing-remitting course of the disease,
whereas 12% were classified as having a progressive course of the
disease.
Inclusion criteria were as follows: definite diagnosis of MS
according to the standard International criteria; more than 18
years old; fluent Italian speakers. Patients under high dosage of
corticosteroids at the time of the recruitment were temporarily
excluded, and they were administered the neuropsychological
battery one month after the interruption of the drug treatment.
Exclusion criteria were as follows: presence of severe psychiatric
disorders such as psychosis or bipolar disorder; presence of severe
medical conditions other than MS such as diabetes, stroke or
traumatic brain injury; drug or alcohol abuse; suicide attempts;
overt dementia; and serious eye disorders (such as diplopia).
Two hundred seventy nine healthy controls (84 males and 195
females) were recruited among the health professionals working at
the University Hospital ‘‘San Luigi Gonzaga’’ of Orbassano (Italy)
and among the caregivers of patients admitted to the various
departments of the hospital. None of the healthy controls recruited
were consanguineous of the patients with MS involved in the
present study. Through a brief clinical interview based on the one
reported by Green [19], it was established that none of the healthy
controls recruited had a positive history of neurological or
psychiatric disorders, of alcohol and drug abuse, or serious
medical conditions.
Procedure
The participants were administered the neuropsychological and
neuropsychiatric measures detailed below at the University
Hospital ‘‘San Luigi Gonzaga’’ of Orbassano (Italy) by expert
clinical neuropsychologists (MB, SC, FS).
Neuropsychological measures. All of the participants were
administered the Brief Repeatable Battery of Neuropsychological
Tests (BRB-N) for Multiple Sclerosis [16] (Rao & the Cognitive
Study Group of the National Multiple Sclerosis Society, 1990), a
neuropsychological battery sensitive to the cognitive deficits that
typically characterize MS. The BRB-N encompasses the following
tests: the Selective Reminding Test (SRT), a test for verbal
memory that provides measurement of learning and delayed recall
capacity. It yields three different scores: the Selective Reminding
Test-Long Term Storage (SRT-LTS), that provides a measure of
the storage capacity in long-term memory; the Selective Remind-
ing Test-Consistent Long Term Retrieval (SRT-CLTR), that
provides a measure of the consistency of the recovery in long-term
memory; the Selective Reminding Test-Delayed (SRT-D) a
delayed recall of the words of the previously learned. The Spatial
Recall Test (SPART), a test of learning and delayed recall of visuo-
spatial items. It yields two scores: the SPART immediate recall
score, and the SPART delayed recall score. The Symbol Digit
Modalities Test (SMDT), a test of attention and of speed of
information processing. The Paced Auditory Serial Addition Test
(PASAT), that assesses the speed of information processing, the
working memory, and the sustained attention. It encompasses two
separate sub-tests (PASAT-2 and PASAT-3) in which the interval
between two consecutive items changes (2 or 3 seconds, respec-
tively). Finally, the Word List Generation (WLG), a semantic
verbal fluency task.
To operationally define the construct of ‘cognitive impairment’,
we used the criteria proposed by Amato et al. [20], a failure in at
least two BRB-N tests, with scores at least 1.5 SD below the scores
of healthy controls. Thus, if a patient had zero or one BRB-N test
score at least 1.5 SD below that of healthy controls the patient was
considered to have no cognitive impairment. If a patient had two
or more BRB-N test scores at least 1.5 SD below that of healthy
controls, the patient was considered to have cognitive impairment.
In order to differentiate the degree of severity of deficits, if a
patient had two BRB-N test scores below that of healthy controls ,
the patient was considered to have a mild degree of cognitive
impairment. If a patient had three BRB-N test scores below that of
healthy controls, the patient was considered to have moderate
cognitive impairment. Finally, if a patient had four or more BRB-
N test scores below that of healthy controls, the patient was
considered to have severe cognitive impairment.
Furthermore, two additional cognitive measures were adminis-
tered to all of the participants: the Brief Intelligence Test (TIB;
[21]), functionally equivalent to the National Adult Reading Test
[22]; and the sub-test Vocabulary of the Wechsler Adult
Intelligence Scale [23]. Both of them are well established measures
aiming at estimating the pre-morbid Intelligence Quotient (TIB),
and the level of verbal intellectual functioning (Vocabulary).
Determinants of Cognitive Impairment in MS
PLOS ONE | www.plosone.org 2 July 2013 | Volume 8 | Issue 7 | e69820
Neuropsychiatric measures. The participants were admin-
istered the following two measures: the Hospital Anxiety and
Depression Scale (HADS; [24]), a 14-item self-assessment scale
that provides a valid and reliable measure of severity of anxiety
and depression; and the Fatigue Severity Scale (FSS; [25]), a nine-
item one-dimensional questionnaire assessing the severity of
fatigue.
Lastly, patients with MS received a score from their neurologists
on the Expanded Disability Status Scale (EDSS, [26]), to monitor
their level of disability presented at the time of the current
neuropsychological assessment.
Statistical analyses
Parametric tests were used due to the large sample size and
because the graphical exploration of the data by means of box
plots and Q-Q plots indicated an acceptable distribution of the
variables of interest. Statistical analyses were as follows: first, the
comparison of the two groups (patients and healthy controls) on
the demographic and clinical variables was performed via a series
of t-tests. Second, in order to take into account the possible
different profile of patients with different course of the MS [27],
MS patients were divided into two sub-groups: patients with a
relapsing-remitting course of MS (i.e. RR-MS), and patients with a
progressive course of MS (i.e. prog-MS). These three groups (RR-
MS, prog-MS, and healthy controls) were compared on the
demographic and clinical variables via an ANOVA procedure,
with Hochberg’s GT2 post-hoc test. Third, participants’ perfor-
mances on the neuropsychological measures were compared via t-
tests or ANOVAs, as appropriate. Finally, we performed multiple
regression analyses in order to identify the significant predictors of
the BRB-N test scores more sensitive to cognitive impairment in
MS (SRT, SDMT, and PASAT-3), as well as simple and multiple
logistic regression analyses in order to detect the influence of
demographic and clinical variables on the presence of significant
cognitive impairment in MS.
A p value,0.05 was accepted as statistically significant
throughout all analyses. Statistical analyses were performed using
SPSS version 18.0 (Statistical Package for the Social Sciences).
Results
First, we identified the presence and the degree of cognitive
impairment in our sample of patients with MS according to the
definition of cognitive impairment used by Amato et al. [20]
previously reported. One-hundred ninety-five patients (195/303,
64.4%) did not show the presence of cognitive impairment. One-
hundred and eight patients (108/303, 35.6%) presented with some
degree of cognitive impairment at the time of testing, in keeping
with previous studies [28]. Of those with cognitive impairment,
34/108 (31.5%) presented with a mild degree of cognitive
impairment; 31/108 (28.7%) with a moderate cognitive impair-
ment; 43/108 (39.8%) presented with a severe cognitive impair-
ment.
Patients with MS versus healthy controls
The two groups of participants were well matched for age
(t(580) = 1.863, NS), gender (x
2,0.001, NS), and years of formal
education (t(580) = 1.273, NS).
Neuropsychiatric measures. Regarding the HADS, five
patients and one healthy control refused to complete the measure.
One patient and five healthy controls did not complete the FSS at
the time of the neuropsychological assessment. All of the other
scores have been collected and used in the statistical analyses. As
expected, the two groups of participants (patients with MS and
healthy controls) differed in HADS-anxiety (t(571) = 2.212, p,0.05)
and HADS-depression (t(571) = 4.503, p,0.01). In addition, the
level of fatigue, FSS, was significantly different too (t(574) = 10.395,
p,0.01). This is in line with previous studies that repeatedly
showed the presence of neuropsychiatric symptoms in patients
with MS, as compared to healthy controls. Table 1 reports the
demographic and neuropsychiatric variables of interest.
Neuropsychological measures. Regarding the neuropsy-
chological measures, one patient did not complete the SRT-LTS
and the SRT-CLTR scores. Twelve patients and six healthy
controls did not complete the PASAT-3, and 28 patients and 10
healthy controls refused to do the PASAT-2, due to the high
cognitive demand of these two tasks. Two patients did not perform
the WLG and the subtest Vocabulary (WAIS), and one healthy
control did not perform the TIB, due to time constraints. All of the
other scores were collected and used in the statistical analyses. As
expected, patients and healthy controls differed in all of the BRB
neuropsychological tests. However, it is relevant to note that the
two groups were well matched for pre-morbid IQ, as measured by
the TIB (t(579) = 1.041, NS). In addition, the number of errors on
the TIB did not differ significantly between the two groups of
participants (t(579) = 0.738, NS). Table 2 reports the details of the
performance on the neuropsychological tests.
Patients with RR-MS versus patients with prog-MS versus
healthy controls
Neuropsychiatric measures. The three groups of partici-
pants did not differ in the level of anxiety (F(2,570) = 2.667, NS),
whereas they differed in the levels of depression (F(2,570) = 19.776,
p,0.01), with both the RR-MS and the prog-MS patients groups
presenting with a higher level of depression, as compared to
healthy controls. In addition, the level of fatigue was significantly
different (F(2,573) = 55.417, p,0.01), with both RR-MS and prog-
MS patients presenting with a higher level of fatigue compared to
healthy controls. Table 3 reports the demographic and neuropsy-
chiatric variables of interest. Hochberg’s GT2 post-hoc test was
used.
Neuropsychological measures. In keeping with previous
studies, prog-MS patients showed a more pronounced pattern of
neuropsychological deficits, as compared to RR-MS patients. In
all of the BRB-N measures, prog-MS patients had significantly
lower scores than healthy controls, whereas RR-MS had lower
scores than healthy controls’ in most measures. In addition, in all
of the measures (with the exception of the SPART score), prog-MS
patients had significantly lower scores than RR-MS patients. In
summary, prog-MS patients had the lowest scores and significantly
differed from both RR-MS patients and healthy controls on the
SRT-LTS, SRT-CLTR, SDMT, PASAT-3, PASAT-2, SRT-D,
SPART-D, and WLG tests. In other words, the scores of the three
groups of participants for each BRB measure laid on a
‘continuum’, ranging from prog-MS patients’ score (the ‘lowest’
score) through RR-MS patients’ score (the ‘intermediate’ score) to
healthy controls’ score (the ‘highest’ score). It is relevant to note
that the three groups did not differ in terms of number of errors on
the TIB (F(2,578) = 2.590, NS), whereas the prog-MS patients differ
in terms of TIB pre-morbid IQ (F(2,578) = 3.881, p,0.05) and
WAIS Vocabulary (F(2,577) = 12.068, p,0.01) from the other two
groups. Interestingly, RR-SM patients and healthy controls did
not differ from one another on TIB pre-morbid IQ and WAIS
Vocabulary. Table 4 reports the details of the performance of the
three groups on the neuropsychological tests. Hochberg’s GT2
post-hoc test was used.
Determinants of Cognitive Impairment in MS
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Predictors of SRT, SDMT, and PASAT-3 scores
According to Portaccio et al. [17], three tests of the BRB-N
(SRT, SDMT and PASAT-3) are very sensitive in detecting
cognitive impairment in MS (sensitivity of 94%, specificity of 84%,
and accuracy of 89%). Thus, we focused on the significant
predictors of these tests scores by considering firstly all of the
participants in our analyses, and secondly only the patients with
MS. The dichotomous variable ‘‘gender’’ was codified as 0 for
males and 1 for females. The categorical variable ‘‘group’’
encompassed three distinct modalities (i.e. healthy controls, RR-
MS patients, and prog-MS patients) and then could not be entered
directly into the statistical models. Thus, we coded healthy controls
as 0, RR-MS patients as 1, and prog-MS patients as 2. Healthy
controls were used as a baseline, and we performed dummy coding
to get two independent dichotomous variables (i.e. ‘‘relapse’’ and
‘‘prog’’) to represent RR-MS patients and prog-MS patients in
multivariate statistical models (backward procedure).
Regarding the SRT-LTS score, the significant predictors were
‘‘prog’’ (b=20.245, p,0.001), ‘‘relapse’’(b=20.170, p,0.001),
‘‘age’’(b=20.289, p,0.001), ‘‘WAIS-Voc’’(b=0.239, p,0.001),
‘‘education’’ (b=20.260, p,0.001), ‘‘gender’’ (b=0.100,
p = 0.007), and ‘‘FSS’’ (b=20.119, p = 0.009). The statistical
model encompassing these significant predictors yielded an
Adjusted R2= 0.246, leading to a 24.60% of variance explained.
Table 1. Demographic and clinical variables of patients with MS and healthy controls.
Variable MS patients mean (SD) healthy controls mean (SD) t-test (df) or x2
(n =303) (n =279)
Participants’ characteristics
Age in years 43.07 (10.79) 44.80 (11.70) 1.863 (580) NS
Gender (M:F) 91:212 84:195 x2,0.001 NS
Education in years 12.76 (3.64) 13.16 (4.04) 1.273 (580) NS
Duration of illness in years 10.87 (7.26) - -
Clinical measures
HADS–anxiety 6.74 (3.58) 6.09 (3.45) 2.212 (571)*
HADS–depression 5.84 (3.92) 4.50 (3.15) 4.503 (571)**
HADS–total 12.58 (6.75) 10.58 (5.93) 3.749 (571)**
FSS 36.23 (15.21) 24.36 (11.78) 10.395 (574)**
EDSS 2.43 (1.92) - -
*p,0.05;
**p,0.01;
df = degrees of freedom; EDSS = Expanded Disability Status Scale; FSS = Fatigue Severity Scale; HADS =Hospital Anxiety and Depression Scale; NS =Not Significant.
doi:10.1371/journal.pone.0069820.t001
Table 2. Neuropsychological measures in patients with MS and healthy controls.
Variable MS patients mean (SD) healthy controls mean (SD) t-test (df)
(n = 303) (n=279)
WAIS–Voc 45.01 (12.12) 48.01 (12.37) 2.957 (578)**
TIB–IQ 111.70 (6.56) 112.27 (6.63) 1.041 (579) NS
TIB–errors 4.53 (5.32) 4.21 (5.09) 0.738 (579) NS
SRT–LTS 37.89 (14.46) 44.45 (13.13) 5.704 (579)**
SRT–CLTR 27.50 (14.42) 34.89 (14.70) 6.108 (579)**
SPART 18.41 (5.29) 19.90 (4.61) 3.624 (580)**
SDMT 46.41 (13.10) 51.72 (10.32) 5.401 (580)**
PASAT–3 38.02 (13.60) 40.97 (11.86) 2.731 (562)**
PASAT–2 27.17 (10.57) 30.75 (10.27) 4.013 (542)**
SRT–D 7.30 (2.51) 8.28 (2.24) 4.928 (580)**
SPART–D 6.43 (2.30) 6.94 (2.00) 2.860 (580)**
WLG 22.28 (5.72) 23.28 (5.51) 2.131 (578)*
*p,0.05;
**p,0.01;
df = degrees of freedom; NS=Not Significant; PASAT =Paced Auditory Serial Addition Test; SDMT= Symbol Digit Modalities Test; SPART = Spatial Recall Test; SPART–
D= Spatial Recall Test-Delayed; SRT–CLTR= Selective Reminding Test-Consistent Long Term Retrieval; SRT–D= Selective Reminding Test-Delayed; SRT–LTS = Selective
Reminding test-Long Term Storage; TIB–errors = Brief Intelligence Test-Errors; TIB–IQ = Brief Intelligence Test–Intelligence Quotient; WAIS–Voc =WAIS Vocabulary;
WLG=Word List Generation.
doi:10.1371/journal.pone.0069820.t002
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Regarding the SRT-CLTR score, the significant predictors
were ‘‘prog’’ (b=20.237, p,0.001), ‘‘relapse’’(b=20.225,
p,0.001), ‘‘age’’(b=20.300, p,0.001), ‘‘WAIS-Voc’’
(b=0.292, p,0.001), and ‘‘education’’ (b=20.258, p,0.001.
The statistical model encompassing these significant predictors
yielded an Adjusted R2= 0.217, leading to a 21.70% of variance
explained.
Table 3. Demographic and clinical variables of patients with RR–MS, progressive MS, and healthy controls.
Variable
RR-MS patients mean
(SD)
prog-MS patients
mean (SD)
healthy controls mean
(SD) F or t-test
(n = 267) (n =36) (n =279)
Participants’ characteristics
Age in years 41.65 (9.98) 53.59 (10.85) 44.80 (11.70) 20.905** "1
Gender (M:F) 77:190 14:22 84:195 -
Education in years 12.96 (3.64) 11.25 (3.37) 13.16 (4.04) 4.000* "1
Duration of illness in years 10.31 (7.04) 15.06 (7.61) - 3.760**
Clinical measures
HADS–anxiety 6.69 (3.53) 7.12 (3.96) 6.09 (3.45) 2.667 NS
HADS–depression 5.52 (3.67) 8.29 (4.89) 4.50 (3.15) 19.776** "1
HADS–total 12.21 (6.53) 15.41 (7.79) 10.58 (5.93) 0.731 NS
FSS 35.77 (14.96) 39.61 (16.80) 24.36 (11.78) 55.417** 1
EDSS 2.04 (1.59) 5.29 (1.68) - 11.393**
*p,0.05;
**p,0.01;
EDSS = Expanded Disability Status Scale; FSS = Fatigue Severity Scale; HADS =Hospital Anxiety and Depression Scale; NS =Not Significant; RR–MS= Relapsing-remitting
Multiple Sclerosis; prog–MS = Progressive Multiple Sclerosis;
"prog–MS significantly different from RR–MS;
1prog–MS significantly different from healthy controls;
RR–MS significantly different from healthy controls.
doi:10.1371/journal.pone.0069820.t003
Table 4. Neuropsychological measures in patients with RR–MS, progressive MS, and healthy controls.
Variable RR-MS patients mean (SD)
prog-MS patients mean
(SD) healthy controls mean (SD) F
(n =267) (n=36) (n=279)
WAIS–Voc 46.01 (11.46) 37.64 (14.33) 48.01 (12.37) 12.068** "1
TIB–IQ 112.06 (6.32) 109.05 (7.76) 112.27 (6.63) 3.881* "1
TIB–errors 4.29 (5.06) 6.28 (6.81) 4.21 (5.09) 2.509 NS
SRT–LTS 39.68 (13.66) 24.24 (13.20) 44.45 (13.13) 38.006** "1
SRT–CLTR 29.10 (14.10) 15.35 (10.66) 34.89 (14.70) 34.019** "1
SPART 18.66 (5.38) 16.62 (4.22) 19.90 (4.61) 9.284** 1
SDMT 47.93 (12.27) 35.10 (13.66) 51.72 (10.32) 35.414** "1
PASAT–3 38.98 (13.05) 30.78 (15.60) 40.97 (11.86) 10.107** "1
PASAT–2 27.94 (10.28) 21.03 (10.94) 30.75 (10.27) 14.406** "1
SRT–D 7.60 (2.38) 5.09 (2.37) 8.28 (2.24) 31.546** "1
SPART–D 6.54 (2.32) 5.61 (1.95) 6.94 (2.00) 7.022** "1
WLG 22.72 (5.61) 18.95 (5.49) 23.28 (5.51) 9.455** "1
*p,0.05;
**p,0.01;
NS =Not Significant; PASAT=Paced Auditory Serial Addition Test; SDMT= Symbol Digit Modalities Test; SPART = Spatial Recall Test; SPART–D= Spatial Recall Test-
Delayed; SRT–CLTR= Selective Reminding Test-Consistent Long Term Retrieval; SRT–D= Selective Reminding Test–Delayed; SRT–LTS = Selective Reminding test–Long
Term Storage; TIB–errors = Brief Intelligence Test–Errors; TIB–IQ = Brief Intelligence Test–Intelligence Quotient; WAIS–Voc =WAIS Vocabulary; WLG=Word List
Generation;
"prog–MS significantly different from RR–MS;
1prog–MS significantly different from healthy controls;
RR–MS significantly different from healthy controls.
doi:10.1371/journal.pone.0069820.t004
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Regarding the SRT-D score, the significant predictors were
‘‘prog’’ (b=20.206, p,0.001), ‘‘relapse’’(b=20.131, p = 0.02),
‘‘age’’(b=20.304, p,0.001), ‘‘WAIS-Voc’’ (b=0.288, p,0.001),
‘‘education’’ (b=20.233, p,0.001), ‘‘FSS’’(b=20.139,
p = 0.003), and ‘‘HADS anxiety ’’ (b=0.109, p = 0.011). The
statistical model encompassing these significant predictors yielded
an Adjusted R2= 0.226, leading to a 22.60% of variance
explained.
Regarding the SDMT score, the significant predictors were
‘‘prog’’ (b=20.199, p,0.001), ‘‘relapse’’(b=20.170, p,0.001),
‘‘age’’(b=20.416, p,0.001), ‘‘WAIS-Voc’’ (b=0.154, p = 0.003),
‘‘education’’ (b=20.322, p,0.001), ‘‘TIB-errors’’ (b=20.250,
p,0.001), and ‘‘FSS’’(b=20.124, p = 0.001). The statistical
model encompassing these significant predictors yielded an
Adjusted R2= 0.331, leading to a 33.10% of variance explained.
Finally, regarding the PASAT-3 score, the significant predictors
were ‘‘prog’’ (b=20.159, p,0.001), ‘‘relapse’’(b=20.107,
p = 0.006), ‘‘age’’(b=20.146, p,0.001), ‘‘WAIS-Voc’’
(b=0.221, p,0.001), ‘‘education’’ (b=20.484, p,0.001), ‘‘gen-
der’’ (b=20.183, p,0.001), and ‘‘TIB-errors’’ (b=20.252,
p,0.001). The statistical model encompassing these significant
predictors yielded an Adjusted R2= 0.234, leading to a 23.40% of
variance explained.
It is relevant to note that we repeated all of the previous analyses
considering the group of MS patients only. The variable ‘‘course of
the disease’’ codified RR-MS patients as 1, and prog-MS patients
as 2. The results were as follows: regarding the SRT-LTS score,
the significant predictors were ‘‘course of the disease’’ (b=20.176,
p = 0.001), ‘‘age’’(b=20.291, p,0.001), ‘‘education’’
(b=20.230, p,0.001), ‘‘WAIS-Voc’’ (b=0.319, p,0.001), and
‘‘HADS depression’’ (b=20.159, p = 0.003). The statistical model
encompassing these significant predictors yielded an Adjusted
R2= 0.271, leading to a 27.10% of variance explained.
Regarding the SRT-CLTR score, the significant predictors
were ‘‘course of the disease’’ (b=20.135, p= 0.016), ‘‘age’’
(b=20.316, p,0.001), ‘‘education’’ (b=20.265, p,0.001),
‘‘WAIS-Voc’’ (b=0.295, p,0.001), and ‘‘HADS depression’’
(b=20.199, p = 0.004). The statistical model encompassing these
significant predictors yielded an Adjusted R2= 0.246, leading to a
24.60% of variance explained.
Regarding the SRT-D score, the significant predictors were
‘‘course of the disease’’ (b=20.144, p = 0.010), ‘‘age’’
(b=20.278, p,0.001), ‘‘education’’ (b=20.246, p,0.001),
‘‘WAIS-Voc’’ (b=0.310, p,0.001), ‘‘HADS anxiety’’ (b=0.186,
p = 0.004), and ‘‘HADS depression’’ (b=20.258, p,0.001). The
statistical model encompassing these significant predictors yielded
an Adjusted R2= 0.260, leading to a 26.00% of variance
explained.
Regarding the SDMT score, the significant predictors were
‘‘course of the disease’’ (b=20.107, p = 0.041), ‘‘age’’
(b=20.432, p,0.001), ‘‘education’’ (b=20.400, p,0.001),
‘‘WAIS-Voc’’ (b=0.179, p = 0.008), ‘‘TIB-errors’’ (b=20.219,
p = 0.001), and ‘‘HADS depression’’ (b=20.155, p = 0.002). The
statistical model encompassing these significant predictors yielded
an Adjusted R2= 0.335, leading to a 33.50% of variance
explained.
Finally, regarding the PASAT-3 score, the significant predictors
were ‘‘course of the disease’’ (b=20.116, p= 0.042), ‘‘age’’
(b=20.232, p,0.001), ‘‘education’’ (b=20.507, p,0.001),
‘‘gender’’ (b=20.163, p = 0.003), ‘‘WAIS-Voc’’ (b=0.172,
p = 0.019), and ‘‘TIB errors’’ (b=20.245, p,0.001). The
statistical model encompassing these significant predictors yielded
an Adjusted R2= 0.234, leading to a 23.40% of variance
explained.
Determinants of the presence of cognitive impairment in
MS
In order to investigate which demographic and clinical factors
may play a significant role in determining the presence or not of
cognitive impairment in patients with MS, we performed simple
and multiple logistic regression analyses with the presence of
significant cognitive impairment in the group of MS patients as the
dependent variable (YES/NO). As the size of the two groups of
patients (RR-MS and prog-MS) was different, we performed two
separate analyses for the two groups. We considered as presence of
cognitive impairment (YES) having two or more BRB-N tests with
scores at least 1.5 SD below the scores of healthy controls, whereas
we considered as absence of cognitive impairment (NO) having
zero or one BRB-N tests with scores at least 1.5 SD below the
scores of healthy controls. We considered as potential predictors
the following factors: ‘‘gender’’, ‘‘education’’, ‘‘age’’, ‘‘duration of
illness’’, ‘‘EDSS’’, ‘‘HADS-anxiety’’, ‘‘HADS-depression’’, ‘‘FSS’’,
‘‘WAIS-Voc’’, ‘‘TIB-IQ’’, and ‘‘TIB-errors’’. Regarding the RR-
MS group, the variables ‘‘gender’’, ‘‘education’’, ‘‘HADS-anxiety’’
and ‘‘TIB-IQ’’ did not contribute significantly to the presence/
absence of cognitive impairment in our patients. As expected, the
predictors considered showed a significant degree of correlation.
Firstly, because there is a substantive and meaningful relationship
between factors such as years of illness and EDSS score (i.e. as the
disease progresses, the degree of disability increases). Secondly,
because the large sample size increases the likelihood of getting
significant results. However, it is important to note that the
significant correlations between predictors were low or moderate
in size, and that each predictor still made a significant individual
contribution to the cognitive outcome. Thus, the significant
predictors were combined in a unique statistical model, leading to
the final model encompassing three significant predictors: ‘‘dura-
tion of illness’’, ‘‘EDSS’’, and ‘‘WAIS-Voc’’. Lastly, regarding the
prog-MS group, the predictors considered in the models did not
contribute significantly to the presence/absence of cognitive
Table 5. Logistic Regression (cognitive deficits YES/NO in RR–
MS patients).
Predictor p value
OR (95% CI)
coefficient
Simple Regression Analysis
Age in years 0.040* 1.028 (1.001–1.056)
Duration of illness in years 0.001* 1.068 (1.029–1.109)
EDSS ,0.001** 1.421 (1.201–1.680)
HADS-depression 0.002* 1.119 (1.041–1.204)
FSS 0.001* 1.032 (1.013–1.052)
WAIS-Voc 0.003* 0.964 (0.942–0.987)
TIB-errors 0.009* 1.069 (1.017–1.124)
Multiple Regression Analysis
Duration of illness in years 0.015* 1.053 (1.010–1.097)
EDSS 0.028* 1.247 (1.024–1.517)
WAIS-Voc 0.001* 0.960 (0.936–0.984)
*p,0.05;
**p,0.001;
EDSS = Expanded Disability Status Scale; FSS = Fatigue Severity Scale;
HADS=Hospital Anxiety and Depression Scale; TIB–errors = Brief Intelligence
Test–Errors; TIB–IQ =Brief Intelligence Test–Intelligence Quotient; WAIS–
Voc =WAIS Vocabulary.
doi:10.1371/journal.pone.0069820.t005
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impairment. Tables 5 and 6 report the details of interest for the
RR-MS patients and for the progressive MS patients, respectively.
Discussion
Cognitive impairment is a well-established clinical marker of
MS. Several studies have shown that a significant proportion of
patients with MS suffer from some degree of cognitive impairment
[6,20], leading to the conclusion that cognitive assessment should
be part of the routine clinical assessment of these patients.
However, to date most published studies do not involve large
samples of patients, and specific investigation of the clinical and
demographic determinants of cognitive impairment is lacking. In
the present study, we recruited large samples of patients and
healthy controls who underwent a neuropsychological assessment
by means of a well-established neuropsychological battery (BRB-
N). In addition, we investigated which variables influence
participants’ performance on the neuropsychological measures
most sensitive to detect cognitive deficits in MS, and identified
significant determinants of the presence of cognitive impairment in
MS.
In our study, ‘cognitive impairment’ has been defined opera-
tively as having two or more BRB tests with scores at least 1.5
standard deviations (SD) below the scores of healthy controls.
Although there is no universal agreement on the most appropriate
criterion to define operatively ‘cognitive impairment’ in MS, we
followed this proposal as it has been widely used in previous studies
[20,29], and as it represents a good compromise between being too
stringent and too lax in detecting cognitive impairment in MS. In
keeping with previous studies, a significant proportion of MS
patients (i.e. 35.6%) presented with some degree of cognitive
impairment. As previous literature suggests that the different
course of the disease (RR versus progressive) leads to different
clinical profiles, we initially compared two groups of participants
(MS patients and HC), and then we repeated all of the analyses
after dividing the group of patients in two sub-groups, according to
the course of the disease. For further analyses, the variable ‘‘course
of the disease’’ was incorporated in all the statistical models
examined.
The two groups of participants (MS patients and HC) were well
matched for age, education, and gender. Patients presented with
higher levels of anxiety and depression, as measured by the
HADS. However, it is relevant to note that on average the levels of
both anxiety and depression in the two groups were well below the
clinical borderline range of values (i.e. scores between 8 and 12),
allowing us to exclude on clinical grounds the presence of
significant levels of anxiety or depression in our samples. Patients
and HC still differed in terms of fatigue as measured by the FSS,
with patients presenting higher levels of fatigue than controls.
Regarding their neuropsychological profile, patients had signifi-
cantly lower scores than HC on all of the measures administered,
with the exception of the TIB-IQ, a reliable estimation of verbal
pre-morbid IQ.
When the three groups of participants (RR-MS patients, prog-
MS patients, and HC) were compared, patients with the
progressive forms of the disease were characterized by older age,
higher levels of depression and fatigue, as compared to RR-MS
and HC, and higher level of disability than RR-MS. Regarding
their neuropsychological profile, patients with the progressive form
of the disease had significantly lower scores as compared to both
RR-MS and HC in the vast majority of measures, whereas only in
one measure (SPART) the two sub-groups of patients did not differ
from each other.
These results confirm that patients presenting with the
progressive forms of MS tend to present a more severe clinical
and cognitive profile, as compared to patients with the relapsing-
remitting form of the disease. Therefore we included this variable
in our statistical models in subsequent multiple regression analyses
to account for the significant role played by the different types of
MS in predicting the presence of cognitive impairment.
As previous research identified some BRB-N sub-tests (i.e. SRT,
SDMT, PASAT-3) as the most sensitive ones to detect specific
cognitive impairment in MS [17], we investigated the significant
predictors of these tests scores in all of the participants, and in MS
patients only. In the overall group of participants, a significant
proportion of the SRT-LTS score was explained by the course of
the disease (progressive and relapsing-remitting), the age of
patients, their level of education, their gender, their verbal
competence (as estimated by the WAIS Vocabulary subtest), and
their level of fatigue. A significant proportion of the SRT-CLTR
score was explained by the course of the disease, the age of
patients, their level of education, and their verbal competence.
Lastly, a significant proportion of the SRT-D score was explained
by the course of the disease, the age of patients, their level of
education, their verbal competence, and their levels of fatigue and
anxiety. As the SRT is a test of verbal memory that provides
measurement of learning and delayed recall capacities, it was
expected that younger age, higher level of intelligence, and verbal
competence would be directly associated to higher scores on this
task. As expected, being an MS patient was related to lower scores
on these tasks, with progressive MS patients’ performance more
compromised than RR-MS patients’ performance. However, we
did not expect to identify an inverse relationship between level of
education and the test scores.
Regarding the SDMT, a significant proportion of its score
(adjusted R2= 0.331) was explained by the variables course of the
disease (progressive or relapsing-remitting), age, education, WAIS
Vocabulary, TIB errors, and FSS score. As this task is a measure of
attention and of speed of information processing, it was expected
that younger age, higher level of verbal intelligence, and lower
level of fatigue would be associated with higher scores. Being an
MS patient was related to lower scores on these tasks, with
progressive MS patients’ performance being more compromised
than RR-MS patients’ performance. Again, we did not expect to
detect a significant inverse relationship between level of formal
education and the test score.
Table 6. Logistic Regression (cognitive deficits YES/NO in
prog–MS patients).
Predictor p value
OR (95% CI)
coefficient
Simple Regression Analysis
Age in years NS 1.025 (0.945–1.111)
Duration of illness in years NS 1.024 (0.914–1.148)
EDSS NS 1.253 (0.762–2.061)
HADS-depression NS 1.076 (0.897–1.292)
FSS NS 1.021 (0.971–1.073)
WAIS-Voc NS 0.976 (0.920–1.036)
TIB-errors NS 1.194 (0.941–1.515)
EDSS = Expanded Disability Status Scale; FSS = Fatigue Severity Scale;
HADS=Hospital Anxiety and Depression Scale; NS =Not Significant; TIB–
errors = Brief Intelligence Test–Errors; TIB–IQ =Brief Intelligence Test–
Intelligence Quotient; WAIS–Voc =WAIS Vocabulary.
doi:10.1371/journal.pone.0069820.t006
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Lastly, a significant proportion of the PASAT-3 score (adjusted
R2= 0.234) was explained by the variables course of the disease,
age, gender, education, WAIS Vocabulary, and TIB errors. As this
task measures the speed of information processing, working
memory functions and sustained attention, and as it is one of
the most demanding task of the BRB-N, we expected there would
be a significant role played by various demographic variables (age,
gender) and pre-morbid cognitive measures (WAIS Vocabulary,
TIB) in determining this score. Again, being an MS patient was
related to lower scores on these tasks, with progressive MS
patients’ performance being more compromised than RR-MS
patients’ performance. A significant inverse relationship between
the level of formal education and the test score was detected again.
An open issue remains why our results showed the presence of a
significant inverse relationship between the level of formal
education and these test scores. In fact, intuitively one would
expect that higher levels of education should facilitate performance
on these tasks, but in our pattern of results this was not the case. It
is reasonable to assume that there is not a simple and linear
explanation for this finding. Cognitive deficits are probably related
to the nature and degree of white matter integrity, gray matter
volume, and neural lesions. Thus, it is reasonable to expect that
the degree of neural pathology may actually mediate the
relationship between education and cognitive impairment, that
cannot be meaningfully interpreted per se. However, further
research should specifically investigate the inverse relationship
between level of education and these tests scores, in order to foster
our understanding of this link.
Another interesting point is that when we repeated all of the
statistical analyses by considering MS patients only, the significant
role of fatigue in contributing to the explanation of the cognitive
scores of interest disappeared, while a significant role of depression
appeared. A possible explanation for the first issue is that patients
with MS are characterized by a higher level of fatigue than healthy
controls. When controls were removed from the statistical analyses
the level of fatigue no longer played a significant role in partially
influencing cognitive scores. In other words, when considering MS
patients only, fatigue played the role of a ‘constant’ rather than
that of a significant ‘variable’. More controversial is the second
issue. The level of depressive symptomatology (as measured by
HADS depression) played a significant role in partially influencing
the scores of the SRT and of the SDMT only in the group of MS
patients. As these cognitive tasks are very sensitive to cognitive
deficits in MS and are challenging, it is reasonable to assume that
the presence of depressive symptoms in addition to the neurode-
generative disease can interfere with a satisfactory performance on
these tasks that require an active and persistent involvement of the
subject in terms of both cognitive and motor performance.
However, further research should specifically investigate these two
issues more deeply.
Lastly, we were interested in investigating the contribution of
demographic and clinical factors to the presence (or absence) of
cognitive impairment in our patients. As the size of the two groups
of patients (RR-MS and prog-MS) was different, we decided to
perform two separate analyses for the two groups. Regarding the
RR-MS group, simple logistic regression analyses allowed us to
identify seven variables (age, duration of illness, EDSS, depression,
FSS, WAIS Vocabulary, and TIB errors) as significant individual
predictors of the presence of cognitive impairment. Furthermore,
multiple regression analyses combining these significant predictors
allowed us to identify the duration of illness, the EDSS and the
WAIS Vocabulary as significantly related to the presence of
cognitive impairment. Thus, our results showed that the presence
of cognitive impairment in RR-MS cannot be estimated simply by
considering a single demographic or clinical factor. Conversely,
estimating the possible presence of significant cognitive deficits
requires us to take multiple demographic and clinical factors into
account such as the duration of the disease, patient’s disability
status, and his/her pre-morbid level of verbal competence.
Altogether, the combination of these factors yielded a statistical
model that, while being parsimonious (i.e. it included only three of
the 11 variables considered), presented an acceptable goodness-of-
fit. Thus, this model can be used as a quick ‘screening tool’ to
suggest the possible presence of cognitive impairment in RR-MS,
that obviously will have to be confirmed via the administration of
sensitive neuropsychological batteries. Regarding the prog-MS
group, the predictors considered here did not contribute
significantly to the presence/absence of cognitive impairment.
So, the present findings do not allow us to identify significant
predictors of cognitive impairment in this group of patients.
However, it is reasonable to expect that with a larger sample size it
would be possible to detect significant predictors also in
progressive MS. Thus, further research is needed to investigate
this important issue.
The present study presents some strengths. First, the large
sample size allowed us to obtain reliable data about the presence,
nature and significant determinants of cognitive impairment in
MS. Second, only a few participants did not perform all of the
neuropsychological tests or neuropsychiatric measures used. As we
collected all of the data for the vast majority of participants, we are
confident that our results are representative of the entire samples
recruited and not limited to a portion of them. Finally, considering
not only MS patients as a whole but also splitting the MS patients
into two groups according to the type of MS (i.e. RR-MS, and
prog-MS) allowed us to control for the very relevant clinical factor
represented by the course of the disease, that should be taken into
account also when dealing with the assessment of cognitive deficits
in MS.
The study also presents some limitations. First, although in the
BRB-N the executive functions are underrepresented, due to time
constraints we did not administer adjunctive tests of executive
functions. Thus, it is not possible to completely rule out the
possibility that patients presenting with a mild degree of executive
dysfunction may have not been identified as ‘cognitively impaired’
by our neuropsychological assessment. In addition, we did not
investigate the construct of cognitive reserve, that has been
recently proposed as a possible ‘mediating’ factor for cognitive
deficits in MS.
To conclude, our study corroborated the evidence that cognitive
deficits are a common and important clinical feature of MS that
should be carefully investigated at the early stages of the disease.
As cognitive assessment has not yet gained the status of routine
clinical examination, we strongly support the view that a
neuropsychological screening assessment should be planned as
part of the standard neurological examination of patients,
especially when the demographic and clinical factors of the
patient at hand (such as the type of MS and its duration, the level
of disability status, and his/her pre-morbid level of verbal
competence) suggest that cognitive impairment may be present.
Furthermore, research should put more efforts in boosting the
essential issue of cognitive rehabilitation. Regarding this, both
medication and cognitive rehabilitation options need to be
considered. Data are limited about the significant and stable
effects of immune-modulating agents on cognitive impairment.
However, clinical trials have suggested that such disease modifying
therapies improve some aspects of the cognitive domain [30–31].
Another possible therapeutic option for managing cognitive
disorders in MS encompasses the use of medications for clinical
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symptoms. For example, recent studies suggest that psycho-
stimulants present an opportunity for adjunctive symptomatic
therapy for slowed information processing and deficits of attention
in MS, even if the their results need to be replicated in larger
samples of patients [32–33]. Another promising therapeutic option
is represented by cognitive rehabilitation. Cognitive rehabilitation
in MS is still in its infancy. As noted in authoritative reviews of this
emerging literature [34–35], the current findings about the efficacy
of cognitive rehabilitation are mixed, with some studies showing
encouraging results while others do not.
In conclusion, to date the best management approach appears
to be to investigate the probable presence of cognitive impairment
early during the course of the disease, and to provide timely and
appropriate support for patients and families in order to minimize
the psychological, social and professional impact of cognitive
impairment in their lives. However, at this point there is no
definitive treatment for cognitive deficits in MS. In addition, due
to the fluctuation of cognitive symptoms amongst patients and
during the course of the disease, it will be probably a good choice
to take into due account individual patient’s needs and preferences
when planning cognitive interventions, instead of trying to apply
standard protocols to all patients.
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